• 1
    Cao ZY. Chinese obstetrics and gynecology. Peking: Beijing Publisher, 2004:2153.
  • 2
    Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S, Weinberg RA. The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 1992;17:3125.
  • 3
    Fombonne J, Devouassoux-Shisheboran M, Bouvier R, Droz JP, Benahmed M, Krantic S. Analysis of p16INK4A gene promoter in male germ-cell tumors: identification of a new point mutation. Cancer Detect Prev 2005;29:17.
  • 4
    Child FJ, Scarisbrick JJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. J Invest Dermatol 2002;118:9418.
  • 5
    Nakahara Y, Shintani S, Mihara M, Ueyama Y, Matsumura T. High frequency of homozygous deletion and methylation of p16 (INK4A) gene in oral squamous cell carcinomas. Cancer Lett 2001;163:2218.
  • 6
    Hsu LS, Lee HC, Chau GY, Yin PH, Chi CW, Lui WY. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan. Oncol Rep 2006;15:50711.
  • 7
    Abbaszadegan MR, Raziee HR, Ghafarzadegan K, Shakeri MT, Afsharnezhad S, Ghavamnasiry MR. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma. Int J Gastrointest Cancer 2005;36:4754.
  • 8
    Marchini S, Codegoni AM, Bonazzi C, Chiari S, Broggini M. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours. Br J Cancer 1997;76:1469.
  • 9
    Dong Y, Walsh MD, McGuckin MA. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997;74:5763.
  • 10
    Fujita M, Enomoto T, Haba T et al. Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 1997;74:14855.
  • 11
    Langosch KM, Ocon E, Becker G. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 1998;79:615.
  • 12
    Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations. Gynecol Oncol 2001;83:491500.
  • 13
    Suh SI, Cho JW, Baek WK, Suh MH, Carson DA. Lack of mutation at p16INK4A gene but expression of aberrant p16INK4A RNA transcripts in human ovarian carcinoma. Cancer Lett 2000;153:17582.
  • 14
    Makarla PB, Saboorian MH, Ashfaq R et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 2005;11:53659.
  • 15
    Katsaros D, Cho W, Singal R et al. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 2004;94:68592.
  • 16
    Debniak T, Scott RJ, Huzarski T et al. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005;65:8359.
  • 17
    McCloud JM, Sivakumar R, Greenhough A. et al. p16INK4a polymorphism: associations with tumour progression in patients with sporadic colorectal cancer. Int J Oncol 2004;25:144752.
  • 18
    Miller SA, Dybes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
  • 19
    Sauroja I, Smeds J, Vlaykova T et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000;28:40414.
  • 20
    Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: a molecular ‘hotspot’ for pathology? Nat Med 2000;6:63741.
  • 21
    Aitken J, Welch J, Duffy D et al. CDKN2A variants in a population-based sample of Queensland familial with melanoma. J Natl Cancer Inst 1999;91:44652.
  • 22
    Geddert H, Kiel S, Zotz RB et al. Polymorphism of p16 INK4A and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract. J Cancer Res Clin Oncol 2005;131:8038.
  • 23
    Zheng Y, Shen H, Sturgis EM et al. Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev 2002;11:6405.
  • 24
    Ichikawa Y, Yoshida S, Koyama Y et al. Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 1996;69:46670.
  • 25
    Scully RE. Histological typing of ovarian tumor, 2nd edn. Berlin, Germany: Springer, 1999:344.
  • 26
    Ono K, Tanaka T, Tsunoda T. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 2000;60:500711.
  • 27
    Spurdle AB, Webb PM, Purdie DM, Chen X, Green A, Chenevix-Trench G. Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype. Carcinogenesis 2001;22:6772.
  • 28
    Yang CQ, Chan KY, Ngan HY et al. Single nucleotide polymorphisms of follicle stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis 2006;27:15026.